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Methoxyﬂurane (MOF) a haloether, is an inhalation analgesic agent for emergency relief of pain by self
administration in conscious patients with trauma and associated pain. It is administered under super-
vision of personnel trained in its use. As a consequence of supervised use, intermittent occupational
exposure can occur. An occupational exposure limit has not been established for methoxyﬂurane. Human
clinical and toxicity data have been reviewed and used to derive an occupational exposure limit (referred
to as a maximum exposure level, MEL) according to modern principles. The data set for methoxyﬂurane
is complex given its historical use as anaesthetic. Distinguishing clinical investigations of adverse health
effects following high and prolonged exposure during anaesthesia to assess relatively low and inter-
mittent exposure during occupational exposure requires an evidence based approach to the toxicity
assessment and determination of a critical effect and point of departure. The principal target organs are
the kidney and the central nervous system and there have been rare reports of hepatotoxicity, too.
Methoxyﬂurane is not genotoxic based on in vitro bacterial mutation and in vivo micronucleus tests and
it is not classiﬁable (IARC) as a carcinogenic hazard to humans. The critical effect chosen for development
of a MEL is kidney toxicity. The point of departure (POD) was derived from the concentration response
relationship for kidney toxicity using the benchmark dose method. A MEL of 15 ppm (expressed as an 8 h
time weighted average (TWA)) was derived. The derived MEL is at least 50 times higher than the mean
observed TWA (0.23 ppm) for ambulance workers and medical staff involved in supervising use of
Penthrox. In typical treatment environments (ambulances and treatment rooms) that meet ventilation
requirements the derived MEL is at least 10 times higher than the modelled TWA (1.5 ppm or less) and
the estimated short term peak concentrations are within the MEL. The odour threshold for MOF of 0.13
e0.19 ppm indicates that the odour is detectable well below the MEL. Given the above considerations the
proposed MEL is health protective.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Methoxyﬂurane (MOF) a haloethane, is clear colourless liquid
with a strong sweet fruity odour; CAS no. 76-38-0; MW.164.97 and
speciﬁc gravity 1.4262 at 20 C. It has a relatively low vapour
pressure (relative to other inhalation anaesthetics) of 3 kPa, a very
high blood:gas partition coefﬁcient of 12 and a very high oil:gas
partition coefﬁcient of 970 (DOSE, 1994; Goodman and Gilman,
1980).
Methoxyﬂurane was ﬁrst introduced to clinical practice as an
inhalation anaesthetic in 1960 (Goodman and Gilman, 1980). Itss).
ier Inc. This is an open access articclinical use as an anaesthetic was discouraged in the late 1970’s to
early 1980’s due to reports of dose-related renal tubular damage
(Crandell et al., 1966; Mazze et al., 1971, Mazze, 2006) and the
availability of newer anaesthetic agents. This led to its reduced use
and disappearance from anaesthetic practice by the late 1970s and
ultimately its discontinuation in the United States and Canada in
the 1990s. In September 2005, in responding to a Citizen’s Petition
the US Food and Drug Administration determined that Penthrane
(Abbott Laboratories’ methoxyﬂurane) was withdrawn from the
market for reasons of safety or effectiveness (US FR, 2005).
Methoxyﬂurane was never withdrawn in Australia and New Zea-
land where it has been available at all times as Penthrox® for use in
lower doses as a rapid-acting analgesic for short-term pain relief.
Since 1975, over ﬁve million MOF doses have been supplied. It is
used by ambulance services as a ﬁrst-line analgesic agent and inle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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copies and change of wound dressings. It is also supplied in the UK,
South Africa, the Gulf Area, Eastern Europe, and Latin America.
Methoxyﬂurane is self-administered under the supervision of
trained personnel, by inhalation from a simple hand held green
pen-shaped plastic device, called the ‘Penthrox Inhaler’ or the
‘GreenWhistle’. The device is supplied with or without an activated
carbon (AC) chamber to reduce environmental exposure.
Methoxyﬂurane may be used in open spaces such as roadsides,
sports and ski ﬁelds, or in more conﬁned spaces such as ambu-
lances, doctor’s surgeries, clinics and emergency departments.
Although some countries list an occupational exposure standard
for MOF this is identical to the NIOSH standard (1977) for waste
anaesthetic gases. The NIOSH standard, besides its age (published
in 1977), is of limited relevance to the analgesic use of MOF. It was
set to protect against co-exposure to all inhalation anaesthetics in
operating theatres, including halothane and nitrous oxide, based on
a contemporary concern in the late 1970’s of spontaneous abortion
due to anaesthetic gases and technological considerations for
operating theatre equipment at that time, especially the lack of
scavenging equipment to remove waste anaesthetic gases. It was
not based on the human and animal toxicity dataset for MOF now
available.
As MOF is only used intermittently for short term analgesia one
of the technical challenges in deriving an occupational exposure
level (OEL) for it is the suitability of human data describing the
effects at sub-therapeutic doses to identify a point of departure for
the analysis. Although employed extensively since the 1960’s the
clinical data reported in the medical literature was generated to
report safety, tolerability and efﬁcacy at therapeutic (anaesthetic)
doses. This paper describes the development of an OEL for brief
exposure to lower doses of MOF to produce analgesia following a
review of non-clinical toxicological, pharmacological and phar-
macokinetic data along with clinical pharmacodynamic, pharma-
cokinetic and safety information and the results of controlled
clinical trials as well as the pathogenesis of its principal toxic action
on the kidney. The benchmark dose procedure has been employed
to derive an OEL affording a considerable degree of protection for
exposed workers. The procedure exempliﬁes how contemporary
risk assessment models/approaches can be combined with data
from clinical experience/clinical safety studies to derive a trans-
parent dose response assessment (Silverman et al., 1999).
Given that the term OEL is associated with guidelines and
standards the term is avoided in the abstract and the term MEL,
maximum exposure level, is used within this paper.
This paper derives an MEL for MOF in the light of its odour as
well as typical exposure conditions in occupational settings. A
summary of exposure studies and a volatilization model has been
used to estimate exposure in occupational (ambulance and treat-
ment rooms) settings.
2. Metabolism and toxicokinetics
MOF has a very high blood to gas partition coefﬁcient of 12
(Goodman and Gilman,1980). This means it is readily transferred to
blood during each respiratory cycle, little if any remains in the
alveoli just before the next inhalation, and the time required for
equilibrium to be reached is relatively longer than most other
volatile gases. It alsomeans that the eliminationwill be delayed due
to partitioning to fat. Blood levels following inhalation plateau after
less than 1 h of constant exposure (Cousins and Mazze, 1973).
Toxicokinetic information for MOF is available in human vol-
unteers (n ¼ 12) receiving MOF during anaesthesia (induced by
vapouriser set a 1.5% during induction and 0.3e0.5% for mainte-
nance during the three hour administration (Mazze et al., 1971).Rapid and extensive metabolism was reported with approximately
40->60% of the parent compound converted to metabolites and
approximately 20% excreted unchanged in exhaled air.
Studies in human in vitro hepatic microsomal fractions have
shown that metabolism of MOF is catalysed predominantly by cy-
tochrome P450s. Given that it is inducible by phenobarbital and
ethanol it is likely that a number of isoenzymes is involved in its
metabolism including CYP 2B4, 2D and CYP2E1 (Zhang et al., 2005;
van Dyke, 1973; Yin et al., 1995; Sweeney and Bromilow, 2006). In
humans, CYP2E1 and perhaps 2A6 and 3A4 are present in the
kidney and may be involved in the metabolism of MOF (Kharasch
et al., 1995).
Metabolism occurs via two pathways (Kharasch et al., 2006a, b);
oxidative demethylation and dehalogenation. MOF metabolism
results in at least six excretable metabolites, carbon dioxide, ﬂuo-
ride, oxalic acid, dichloroacetic acid, diﬂuoromethoxyacetic acid
and chloride (Yoshimura et al., 1976). The main focus within this
paper is the formation of ﬂuoride metabolites given their impor-
tance to the mode of action for MOF toxicity.
To assess which strain of rat might serve as an appropriate
model for MOF toxicity, adult male Fischer 344, Buffalo, Wistar,
Sprague Dawley and Long-Evans rats were anaesthetised with 0.5%
(5000 ppm) MOF for three hours. Fischer 344 and Buffalo rats
metabolised MOF to a greater extent than the other three strains.
Serum and urinary ﬂuoride levels in Fischer 344 and Buffalo rats
were greater than in the other strains of rats even though the blood
concentrations of MOF was approximately the same in all strains.
Since only Fischer 344 rats developed biochemical and pathological
evidence of a renal lesion it was evident that kidney damage was
not related to blood levels of MOF but to ﬂuoride metabolites
(Mazze et al., 1973).
Mazze et al. (1972) also investigated the MOF dose response in
Fischer 344 rats for the purpose of delineating the renal toxicity of
MOF. The authors divided 30 rats into ﬁve groups of six rats each.
Concentrations and duration of exposure to MOF were increased in
each of group 1 to 3 from 0.25% for 1.5 h to 0.75% for 6 h. Groups 4
and 5 served as control groups. Urinary ﬂuoride (an excretion
product of MOF metabolism) was measured on a daily basis for
seven days post-anaesthesia. Peak urinary ﬂuoride concentrations
were reached on day three and amounted to approximately 6e8
times the preanaesthetic concentration of urinary ﬂuoride.
Corbett & Ball. (1971) investigated excretion of MOF in end
expired air of patients following prolonged anaesthesia with MOF
and of the anaesthesiologists who administered the anaesthetic.
Anaesthesiologists were exposed to MOF from anaesthetic equip-
ment (Pentec-2-vaporiser with a gas ﬂow of 5 L/minute), which at
the time did not commonly employ scavenging systems (e.g. acti-
vated charcoal). MOF was detectable in end expired air from pa-
tients for 10e18 days after anaesthesia and in anaesthesiologists for
up to 30 h after exposure. Anaesthesiologists were exposed to
1.3e9.8 ppm MOF.
The authors investigated the use of a ‘gas trap’ (a balloon ﬁtted
over the pop-off valve of the anaesthetic apparatus used and
diversion of waste gas to an exhaust system to remove the gas from
the room). The concentrations in the operating room air then
ranged from 0.015 to 0.095 ppm (i.e. 97% efﬁciency in reducing
environmental vapour concentrations). Only two anaesthesiolo-
gists participated in the study and exposures were 130 min,
390min and 300min. Duration of excretionwas found to be related
to the duration of exposure. Table 1 shows the relationship be-
tween duration of exposure and time taken to eliminate MOF to
levels below the detection limit (0.01 ppm).
The anaesthesiologist with an exposure of 130 min had MOF
detectable in end-tidal air for up to 10 h. The anaesthesiologist with
an exposure duration of 390min had an increase in urinary ﬂuoride
Table 1
Methoxyﬂurane elimination following anaesthesiologist exposure (Adapted from Fig 4 e MOF decay curves of anaesthesiologists following administration of anaesthesia
Corbett and Ball., 1971).
Duration of exposure of anaesthesiologist to MOF
(minutes)
Time for elimination of MOF in expired air (ie <0.01 ppm MOF)
(minutes)
Ratio of time for elimination/Duration of
exposure
130 630 4.8
300 1620 5.4
390 1740 4.5
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concentration following a 390 min indoor air exposure to between
1.3 and 9.8 ppm occurred between 12 and 18 h from the beginning
of the operation and was approximately 0.15 mM.
Strum et al., 1991 investigated the pharmacokinetics of simul-
taneous administration of halothane, isoﬂurane, enﬂurane and
methoxyﬂurane (658 ppm) during 30 min of exposure to volun-
teers; including seven healthy young subjects: men (n ¼ 3) and
women (n ¼ 4). Elimination occurred over 5e12 days. The study
conﬁrmed that the elimination of the anaesthetics via expired air
occurred at very similar rates for the different anaesthetics
measured. Expired concentrations of all the anaesthetics dropped
to less than 10% of the original concentration in less than 1 h. After 2
days less than 0.1% of the inhaled concentration was detected in
breath. The slower rate of elimination of the last 10% of MOF was
attributed to the high solubility of MOF in lipid which results in
partitioning to fat tissue followed by slow diffusion from these
sites.
The results of both Corbett and Strum show that sub-anaesthetic
concentrations of MOF are rapidly eliminated following inhalation
and that most of the elimination occurred within several hours of
the end of even prolonged exposure to high anaesthetic doses of
MOF.
3. Hazard identiﬁcation
3.1. CNS effects
The halogenated anaesthetics exhibit four sites of biological
activity; central nervous system depression (amnesia, analgesia,
respiratory depression), cardiovascular system (reduced cardiac
output by 20%e50%, depression of contractility, and production of
arrhythmias), liver dysfunction and nephrotoxicity (inhibits so-
dium chloride reabsorption in the thick ascending limb and inhibits
ADH-mediated reabsorption of water, possibly due to disruption in
adenylate cyclase). These effects occur at high concentrations
(>1000 ppm) (Goodman and Gilman, 1980).
Hosick et al. (1971) investigated cerebral somatosensory po-
tentials by measuring electroencephalogram traces while healthy
human volunteers were exposed to sub-anaesthetic concentrations
of cyclopropane, diethyl ether, methoxyﬂurane and enﬂurane.
Volunteers were asked to respond to electrical stimuli and the re-
sponses recorded. The authors state that end-tidal concentrations
of MOF were too low to measure by gas chromatography (0.008%,
80 ppm detection limit). The inspired concentrations of MOF were
up to 0.38% (3800 ppm) for a duration of up to 2 h. One subject who
received 0.38% for 1 h lost the ability to cooperate at this concen-
tration. Exposure to MOF was ceased and when the subject was
alert, calm and relaxed hewas retested. At this time end-expired air
concentrations could not be measured (below 80 ppm limit of
detection). In low concentrations MOF was found to suppress
evoked potentials with latencies greater than 50 msec; early re-
sponses were unaffected but late response was suppressed and
then returned after further recovery. The subject had difﬁculty
counting and concentrating but was able to recall all phases of thestudy. Four of the six subjects reported were amnesic for part or all
of the study.
Swann et al. exposedmice to various concentrations of MOF and
measured respiratory rate, depth and conﬁguration while the ani-
mals were inhalingMOF. The concentrations usedwere 1000, 2000,
4000, 8000, 16,000, 32,000, 64,000, and 128,000 ppm. Exposures
were for ﬁve minutes. Sporadic body movements but not anaes-
thesia were noted at 1000 ppmwith light anaesthesia at 4000 ppm
and deep anaesthesia with irregular respiration at 32,000 ppm.
In a pilot telemetric evaluation in two beagle dogs exposed to
MOF by inhalation, arterial blood pressure (systolic, diastolic and
derived mean), heart rate (derived from the blood pressure wave-
form), respiration (rate, tidal volume and derived respiratory
minute volume (RMV)) and EEG were monitored. The dogs were
dosed by inhalation for 10e15 min at 0.01, 0.02, 0.04, 0.08, 0.1 and
0.5% (i.e. approx. 100, 200, 400, 800, 1000 and 5000 ppm). Behav-
ioural and clinical observations were conducted predose and at the
end of each dose level exposure, then at approximately 0.5, 1, 2 and
4 h. No adverse effects (clinical or behavioural signs, arterial blood
pressure (systolic, diastolic or mean), heart rate or respiratory pa-
rameters (rate, tidal volume or minute volume) were noted at
concentrations up to 0.1% for 15 min. At 0.5% for 10 min MOF
produced an increase in heart rate, an increase in respiration rate, a
decrease in tidal volume and an increase in minute volume (Hun-
tingdon Life Sciences, 2013).
In a developmental toxicity study (Pope et al., 1978) pregnant
Swiss mice were exposed to either 2 or 60 ppmMOF for 4 h per day
and for 9 days (gestation days 6e15). The authors noted that there
were no adverse behavioural effects and no changes to body weight
gain for exposed dams.
Similarly Sprague-Dawley pregnant rats were exposed for 8 h/
day for 20 days (gestation day 1e21) at 100, 400, and 800 ppmMOF.
The authors did not comment on behavioural effects at 100 or
400 ppm but did note that the maximum concentration was
selected as the ‘maximum tolerated sub-anaesthetic dose’ and that
some animals were somnolent at 800 ppm. No other adverse effects
in the dams were noted (Pope et al., 1978).
Overall the available studies indicate that the acute effects occur
at relatively high concentrations and do not include respiratory
system effects such as respiratory irritation.
3.2. Kidney effects
The kidney toxicity of MOF has been thoroughly investigated in
animals and humans (Kharasch et al., 1995; Kenna and Jones, 1995;
Mazze et al., 1972, 1973; and 1974). The renal injury caused by MOF
is characterised by acute renal failure with accompanying serum
hyperosmolarity, hypernatremia, urinary hypoosmolarity, and
vassopressin resistant polyuria due to proximal tubular damage.
These changes are associated with the inhibitory effects of the
metabolite ﬂuoride on solute and water reabsorption
(Schnellmann, 2013; Hoffman et al., 2002). Fluoride inhibits so-
dium chloride reabsorption in the thick ascending limb and inhibits
ADH-mediated reabsorption of water, possibly due to inhibition of
adenylate cyclase (Mazze et al., 1973; Schnellmann, 2013; Hoffman
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Clinical investigations have found the severity of kidney damage
to be proportional to the dose of MOF administered to patients
(Cousins andMazze, 1973). Mazze et al. (1972,1973, and 1974) were
able to reproduce dose-related MOF nephrotoxicity in the F344
strain of rat and to demonstrate the cardinal importance of ﬂuoride
in the pathogenesis of the renal lesion.
Prospective clinical studies have indicated the threshold peak
serum concentration of ﬂuoride above which kidney damage oc-
curs in humans is 40 mmol/litre as produced after a dose of 2.0 MAC
(minimal alveolar concentration) hours (approx. equivalent to
192,000 ppm min) (Cousins and Mazze, 1973). Thus ﬂuoride pro-
duction is proportional to the inhaled concentration of MOF and
duration of exposure time.
Two anaesthesiologists were exposed to 1.3e9.8 ppm MOF for
130 min, 390 min or 300 min (Corbett and Ball, 1971). Duration of
excretion of ﬂuoride was found to be related to the duration of
exposure. The mean urinary ﬂuoride concentration following a
390min exposure of between 1.3 and 9.8 ppmwas 0.15 mmol with a
peak occurring approximately 5.5e8.5 h after exposure.3.3. Liver effects
Severe liver toxicity followingMOF exposure during anaesthesia
and analgesia has been observed on very few occasions. It is
described as an “extremely rare” adverse reaction characterised by
clinical and histological features that closely resemble those of
halothane hepatitis. It is postulated that the mechanism is medi-
ated by the immune system perhaps following direct toxicity of
reactive metabolites (Kenna and Jones, 1995).
Adaptive changes in biochemical markers and liver function
adverse effects have been reported in animal toxicity studies
following single or repeat exposure. Although the data available for
this endpoint is limited adverse effects have only been observed at
high concentrations.
No renal effects were reported in male and female Wistar rats,
Guinea pigs or rabbits exposed to a sub-anaesthetic dose of
200 ppm (0.02%) MOF in air for 7 h/day, 5 days per week and a total
period of 7 weeks (Chenoweth et al., 1972; equivalent to
84,000 ppm min). Hepatic changes were observed, consisting of
minimal focal fatty metamorphosis in rats, minimal to marked
centrilobular fatty metamorphosis in Guinea pigs, and minimal
centrilobular fatty metamorphosis in rabbits. In the latter species,
hepatic ﬁndings were occasionally accompanied by elevated serum
levels of alanine aminotransferase (ALT) and aspartate amino-
transferase (AST).
In 12 male (Fischer 344) rats, continuously exposed to MOF
vapour at a sub-anaesthetic dose of 50 ppm for a period of 14weeks
(equivalent to 6,480,000 ppm min), reduced body weights were
observed at the end of the treatment period (approximately 60%
decrease in comparison to controls) (Plummer et al., 1985). MOF
exposure caused an increase of water intake (15e20%) and urinary
volume (indicating nephrotoxicity). These effects were relatively
mild, were not accompanied by kidney histopathological changes,
and were fully reversible after a 4-week recovery period. Serum
alanine amino transferase ALT was markedly enhanced and liver
weight relative to body weight was increased. Hepatic cytochrome
P450 levels were signiﬁcantly reduced. Microscopically, the liver
showed a variable extent of fatty metamorphosis, and foci of he-
patocellular degeneration and necrosis. After 4 weeks without
treatment, serum ALT levels had decreased considerably (but not to
control levels), and fat was no longer observed in the liver. Foci of
hepatocellular degeneration and necrosis were however still
present.3.4. Genotoxicity and carcinogenicity
MOF was negative for genotoxicity in both an in vitro bacterial
mutagenicity and in vivo mammalian micronucleus assay.
In a recently conducted (Williams, 2009) Ames test according to
GLP and OECD TG 471, it was concluded that MOF did not induce
mutation in ﬁve histidine-requiring strains (TA98, TA100, TA1535,
TA1537 and TA102) of Salmonella typhimurium when tested in the
plate incorporation assay. Tests occurred at concentrations up to
5000 mg/plate in the absence and presence of a rat liver metabolic
activation system (S-9).
In an in vivo GLP micronucleus test (OECD TG 474) MOF was
administered to Sprague-Dawley CD rats intravenously (25, 50,
100 mg/kg) by bolus injection in the lateral tail vein. No statistically
signiﬁcant increases in the frequency of micronucleated immature
erythrocytes and no substantial decreases in the proportion of
immature erythrocytes were observed in rats treated with MOF at
any treatment level, compared to vehicle control values (Pritchard,
2006).
The International Agency for Research on Cancer (IARC) evalu-
ated general evidence about the carcinogenicity of volatile anaes-
thetics in 1976 and concluded that there was inadequate evidence
of carcinogenicity to animals or humans (Group 3). The conclusion
was conﬁrmed following review in 1987 (IARC, 1987).
3.5. Developmental and reproductive effects
The developmental toxicity of trace, sub-anaesthetic and
anaesthetic exposures to methoxyﬂurane was examined in Swiss/
ICR mice (Wharton et al., 1980). No adverse effects on reproduction
or foetal development were demonstrated following exposure to
trace (2 ppm) and sub-anaesthetic (60 ppm) concentrations of
methoxyﬂurane for 4 h daily on days 6 through 15 of pregnancy.
Exposure to an anaesthetic concentration (2000 ppm; 0.2%) for the
same period resulted in decreased foetal weight, decreased ossiﬁ-
cation, and delayed renal maturation. Additionally, the incidence of
minor skeletal anomalies was increased. It is concluded that
gestational exposure of mice to trace or sub-anaesthetic concen-
trations of methoxyﬂurane does not result in reproductive loss or
morphologic abnormalities in their offspring. The highest NOEL in
this study was 60 ppm.
Mazze et al. (1986) investigated the reproductive and develop-
mental toxicity of halothane, isoﬂurane, enﬂurane and nitrous ox-
ide. Sprague Dawley rats were exposed to 0.8% (800 ppm)
halothane, 1.05% isoﬂurane, 1.65% enﬂurane and 75% nitrous oxide
on pregnancy days 14e16, 11e13, or 8e10. Exposure resulted in
light anaesthesia. Reproductive indices were determined and 5178
offspring were examined for external, internal and skeletal abnor-
malities. There were no major or minor teratologic effects in
anaesthetic treated groups, although several developmental vari-
ants were observed in halothane and enﬂurane treated groups.
Nitrous oxide exposure on days 14e16 resulted in a three-fold in-
crease in foetal resorptions. The results suggest that the volatile
halogenated anaesthetics are not teratogenic.
An abstract by Corbett et al. (1974) reported a study where
pregnant Sprague-Dawley rats were exposed to either 10 or
100 ppm MOF from days 8e15 of pregnancy for 8 h per day. The
authors report that there were no differences between experi-
mental and control groups in number of implantations per rat,
resorptions, foetal anomalies, sex ratio, average foetal crown-rump
length, or average foetal weight. The veracity of these ﬁndings
cannot be conﬁrmed as the authors have not published a full ac-
count of the study in a peer reviewed journal. However the results
are consistent with published studies by Pope et al. (1978), Whar-
ton et al.(1980), Mazze et al. (1986).
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natal survival in mice chronically exposed to halothane at expo-
sures of between 0.05% for 0.5 h/day (h/d), 0.05% for 2 h/d, 0.1% for
4 h/d, 0.3% for 4 h/d, 1.0% for 4 h/d. Exposures to 0.1% (1000 ppm) or
higher resulted in decreased maternal weight gain, decreased
foetal length and weight and early postnatal weight gain. No
adverse effects on reproduction were noted at the two lowest
exposure levels studied. Pregnancy rate, implantation rate and
number of live foetuses per litter were decreased at 0.3%
(3000 ppm) halothane. The NOEL for halothane in this study was
0.05% (500 ppm).
Epididymal spermatozoa of mice were examined for morpho-
logical abnormalities following exposure to 0.1 MAC or higher
concentrations of anaesthetics (MOF (0.01 and 0.1%,
100e1000 ppm) for 4 h per day for 5 days (20 exposure hours).
Twenty eight days after exposure epididymal spermatozoa were
examined. No changes in the percentages of abnormal spermatozoa
were found in either MOF exposure group (Land et al., 1981). A
number of reviewers have commented on exposure to anaesthetic
gases and reproductive/developmental outcome (Boivin, 1997;
Tannenbaum and Goldberg, 1985; Ferstandig, 1978; NIOSH, 1977;
and NH&MRC, 1977). Furthermore a number of studies have
investigated MOF (or other volatile anaesthetics) for reproductive
and developmental toxicity in rats and mice (Pope et al., 1978,
Wharton et al., 1980, Mazze et al., 1986, Wharton et al., 1978, Land
et al., 1981). Some reviews of occupational risks due to exposure to
anaesthetic gases (noting that many of these did not include
assessment of MOF exposure) suggest an increased risk of spon-
taneous abortion (Boivin, 1997; NIOSH, 1977 and NH&MRC, 1977).
Animal studies investigating the reproductive and develop-
mental toxicity of MOF consistently show that MOF is neither
teratogenic nor causes reproductive effects at sub-anaesthetic ex-
posures at non-maternally toxic doses.
Boivin (1997) conducted a meta-analysis of published epide-
miological studies investigating the association between maternal
occupational exposure to anaesthetic gases and risk of spontaneous
abortion. The overall relative risk was 1.48 (95% conﬁdence interval
[95%CI], 1.4 to 1.58). Utilising only those studies rated by the au-
thors as rigorous the estimate of risk increased to 1.9 (95% CI: 1.72
to 2.09). They conclude that data obtained in the era where pre-
scavenging of anaesthetic gases was not performed indicate an
increased risk of spontaneous abortion. The most commonly used
anaesthetics within the study period (studies published between
1971 and 1995) were halothane and nitrous oxide. The study does
not include analysis of causal relationships with any particular
anaesthetic. It is unclear whether the studies controlled for other
risk factors such as ionising radiation (e.g. dentistry and veterinary
practices) and pesticide exposure (veterinary practices). It is noted
thatmany of the reviewed studies had deﬁciencies andwhere these
could be identiﬁed they were subjectively weighted by the authors.
Tannenbaum and Goldberg (1985) reviewed the epidemiolog-
ical literature concerning occupational exposure to trace concen-
trations of anaesthetic gases and reproductive outcomes. They
comment that a variety of evidence suggests that chronic exposure
to incidental low doses of anaesthetic gases, as occurs in the
occupational setting, is a risk factor for spontaneous abortion and
congenital defects. The most commonly used anaesthetics within
the study period (studies published between 1971 and 1995) were
halothane and nitrous oxide. The authors note that there was a
large variability in levels of gas concentrations in operating the-
atres. For instance studies from the 1970s reported nitrous oxide
levels ranging from 130 to 7000 ppm in the anaesthesiologists
breathing zone. The study does not include analysis of causal re-
lationships with any particular anaesthetic. However there are in-
consistencies between studies, arising primarily frominvestigational methodologic problems. For example, lack of
criteria for exposure or outcome, poor survey response rates, se-
lection bias, lack of validation of outcome, recall bias and lack of
control of potentially confounding variables. The authors state
“results from the majority of studies do suggest that there is no in-
crease in spontaneous abortions amongst wives of exposed male
personnel and that there is no increase in birth defects among the
offspring of exposed parents”.
Ferstandig (1978) reviewed the available animal and human
toxicity data for reproductive effects of inhalation anaesthetics. He
concluded that “short exposures to even high concentrations of
inhalation anaesthetics has either no adverse reproductive effects or
has statistically questionable effects”.
Pope et al. (1978) investigated fetotoxicity in rats following
chronic exposure to halothane, nitrous oxide or methoxyﬂurane.
Pregnant Sprague Dawley rats were exposed for 8 h a day
throughout the 21 days of gestation to MOF 0.01%, 0.04% or 0.08%,
(100e800 ppm). Foetal loss in the MOF groups was unchanged
compared to controls and no gross skeletal anomaly related to
exposure was seen, but there was a dose related decrease in foetal
weights, size and development as evidenced by slight skeletal
variations in the ossiﬁcation centres of the metacarpals and pha-
langes. The authors state that dams exposed to the highest con-
centrations were drowsy during exposure. Based on decreased
foetal weight a no effect level (NOEL) was not identiﬁed in this
study. The authors postulate that the effects observed are a general
effect of the anaesthetic on the nutritional status of mother rather
than a direct effect on the foetus.
In summary the animal reproductive studies are negative and
human clinical and epidemiological ﬁndings are insufﬁcient to
conclude a causal relationship.
4. Risk characterisation
The typical practice in developing occupational exposure levels
is to identify an effect level or concentration for the most sensitive
relevant adverse effect as a ‘‘point of departure” (POD) and then
apply factors to address uncertainties in extrapolation from the
identiﬁed effect levels. The present health risk assessment includes
an analysis of the dose-response relationship between occupa-
tional exposure to methoxyﬂurane and health related outcomes
using the benchmark dose modelling approach (BMD) (US EPA,
2012; WHO, 2009; EFSA, 2009). In the case of MOF renal toxicity
was considered to be the critical and most sensitive adverse effect.
To determine the point of departure, benchmark concentration
(BMC) modelling was conducted to estimate a concentration
associated with a 10% extra risk (the BMC10) of subclinical kidney
toxicity (of minimal severity or greater) and a 95% lower conﬁdence
bound concentration estimate (the BMCL10). The benchmark
response level (BMR) is deﬁned as a speciﬁed increase in incidence
over background. A BMR of 10% (extra risk) is used as a default for
quantal data sets (US EPA, 2012; EFSA, 2009) as it is roughly
equivalent to the experimental no observed adverse effect level
(NOAEL). The BMC modelling to derive the POD was conducted
using US EPA software BMDS. Uncertainty factors were applied to
the POD to derive the maximum exposure level (MEL) expressed as
an 8 h time weighted average.
4.1. Selection of critical effect
The key organs associated with MOF toxicity in anaesthetic
doses include; central nervous system (amnesia, analgesia, anaes-
thesia, respiratory depression), cardiovascular system (reduced
cardiac output by 20%e50%, depression of contractility, and pro-
duction of arrhythmias), liver dysfunction and nephrotoxicity (due
Table 2
Study dose groups.
Study population grouping Dose
1a 1.0e1.5 MAC halothane
2 0.5 MAC methoxyﬂurane
3 1.5 MAC methoxyﬂurane
4 1.0 MAC methoxyﬂurane
a Postoperatively, participants who received halothane displayed symptoms of
mild hyponatremia and serum hypoosmolality, with a prompt return to preopera-
tive urine concentrating ability. These symptoms were considered normal for the
control group. Group 1 participants are not discussed further.
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Both the central nervous system and cardiovascular effects are
related to exposure to high concentrations.
Methoxyﬂurane induced liver toxicity in humans has been a
very rare phenomenon after analgesic or anaesthetic exposures.
Although incidental exposure to MOF has been reported to result in
small transient increases in biochemical markers of liver function,
the changes are within or only just outside of normal population
ranges and are therefore not indicative of liver damage. On repeat
exposure (14 weeks at 50 ppm for 1 h per day) animal study did
show direct liver toxicity can occur. It is noted that these effects co-
occurred with serum inorganic ﬂuoride concentrations above
50 mM/L (Plummer et al., 1985).
Kidney toxicity in both animal models and humans is dose-
related, enhanced by enzyme induction and attenuated by
enzyme inhibition. The same pattern of renal damage can be
induced in animals not exposed to MOF by the injection of inor-
ganic ﬂuoride (Cousins and Mazze, 1973; Mazze et al., 1974; Mazze
et al., 1972).
In a carefully designed and controlled clinical study, Cousins and
Mazze (1973) showed that the onset of sub-clinical toxicity in
people did not occur until exposure to MOF exceeded the total
dosage of 2.5 MAC hours, corresponding to a serum inorganic
ﬂuoride concentration of 50 mM/L.
In a recent review (Dayan, 2016) of laboratory and clinical data
relevant to nephrotoxicity and methoxyﬂurane use in analgesia
(since the mid-1960’s) the authors concluded that analgesic use of
methoxyﬂurane was not associated with overt evidence of renal
dysfunction in adults or children. The duration of exposure ranged
from about 6 to 8 min to 40e60 min or more in prehospital and
accident and emergency use as well as obstetrics, brief orthopaedic
and dental procedures and wound dressings. The total number of
healthy subjects and patients amounted to several thousand adults
and children down to the age of 1 year.
Kidney toxicity was selected as the critical effect because it is the
predominant effect observed both on single exposure to high
concentrations and after repeat exposure to lower concentrations.
4.2. Selection of key study
Cousins & Mazze. (1973) investigated the dose-response rela-
tionship between MOF and nephrotoxicity in men. This study was
chosen as the key study as it was the most robust clinical investi-
gation of MOF and kidney toxicity.
The study population consisted of 26 volunteers, all healthymen
scheduled for elective surgery; their ages and weights are not
disclosed. 18 participants received MOF in varying concentrations
and 8 participants, making up the control group, received
halothane.
Anaesthesia was induced with thiopental sodium followed by
succinylcholine chloride and maintained with MOF (or halothane;
not discussed here). The MOF (or halothane) was delivered via
inhaler connected to an anaesthetic vaporiser at a gas ﬂow rate of
6 L/min (for a mean duration of 3.8 ± 0.5 h); MOF (or halothane)
was supplemented with 50% nitrous oxide and 50% oxygen.
The study population were divided into four dose groups as per
Table 2.
MAC is deﬁned as the minimum alveolar concentration to pro-
duce surgical anaesthesia in 50% of healthy patients. According to
Cousins andMazze (1973), 1.0 MACmethoxyﬂurane is equivalent to
0.16 vol % (1600 ppm).
Exposure duration expressed as MAC-hours ranged from 1 to
9 MAC-hours. MAC-hours represent the minimum alveolar con-
centration (%) multiplied by the duration of anaesthesia (h).
The mean exposure duration was 3.8 ± 0.5 h. For Group 2participants (0.5 MAC) exposurewas approximately 2.0 MAC-hours
(3.8 h x 0.5 MAC ¼ 1.9 MAC-hour).
Serum ﬂuoride levels were monitored in this study as a dose-
dependent marker of the effect of methoxyﬂurane. Each volun-
teer was also monitored for signs of nephrotoxicity classiﬁed as:
subclinical, mild clinical and clinical toxicity. Subclinical toxicity
was characterised by delayed return to maximum preoperative
urine osmolality, unresponsiveness to vasopressin administration,
and elevated serum uric acid concentration. In addition to sub-
clinical symptoms, study participants with mild clinical toxicity
were reported to have serum hyperosmolality, hypernatremia,
polyuria, and low urine osmolality (306e372 mOsm/kg). Those
with symptoms of clinical toxicity had more pronounced serum
and urine abnormalities and a reduction in creatinine clearance.
These effects were reversible.4.3. Modelling the point of departure
Cousins and Mazze (1973) plotted their ﬁndings for each
volunteer with respect to dose and serum ﬂuoride levels and the
presentation of symptoms. Individual participant data were only
provided in graphed form so graphing software was utilised to
transform the information into numerical form for further pro-
cessing. This was done by reverse engineering each axis and data
point into a new graph by assigning coordinates to each data point.
Once numerical data were extracted they were converted from
MAC-hours to parts per million concentration in time using the
following equation:
concentration (ppm) x time (min) ¼ ppm.min
1 MAC-hour is approximately 96,000 ppm xminutes (ppm.min)
calculated as 1600 ppm (1 MAC) x 60 min. The extrapolated data
are provided in Table 3 and Fig. 1.
The critical effect level (the mean threshold for toxicity)
described by Cousins & Mazze was found to be approximately
2.5 MAC-hours. Subclinical toxicity was found to occur at exposures
2.5e3.0 MAC-hours which resulted in peak serum ﬂuoride ion
concentration ranging from 50 to 80 mM. There was no evidence of
renal damage after exposure to 2 MAC-hours. Patients receiving
2.0 MAC-hours or less methoxyﬂurane had peak serum ﬂuoride ion
concentrations <40 mM which was not associated with
nephrotoxicity.4.4. Benchmark concentration derivation
Data from Fig. 1 was split into dose groups in order to plot
incidence vs dose using US EPA Benchmark Dose Software (BMDS
Wizard v1.8). The dose-response datawas grouped into dose ranges
(5 dose groupings) as indicated in Fig. 2. The dose range grouping
considers ﬁve distinct groups with regard to observed effects at
ranging concentrations. The grouping of data is important for
Table 3
Extrapolateda Dose-response data from Cousins and Mazze (1973).
Study group X (MAC hours) X (ppm min) Y (ﬂuoride conc. mM)
MAC “0.5” Group Data 1.5 144,000 35
2 192,000 37
2.5 240,000 36
2.75 264,000 31
3 288,000 64
MAC “1” Group Data 1 96,000 23
2 192,000 30
2.5 240,000 50
3 288,000 72.5
3 288,000 77.5
2.5 240,000 94
7 672,000 117
9 864,000 175
MAC “1.5” Group Data 2.75 264,000 41
4.5 432,000 97
5 480,000 90
5 480,000 116
9 864,000 80
a Data from Peak serum inorganic ﬂuoride concentration (F-) and degree of neph-
rotoxicity Fig. 1, was extrapolated using graphing software (DataThief III).
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conﬁdence in the model predictions.
Dose-response grouped data were plotted (dose vs incidence
rate) using US EPA Benchmark Dose Software, BMDS Wizard.
The POD used is based on benchmark dose modelling. The
benchmark dose method involves ﬁtting mathematical models to
dose-response data and using the different results (from the
models employed) to select or derive a BMC that is associated with
the predetermined benchmark response (critical effect). Because
the individual statistical curve ﬁts are approximations only the
average POD from each of these statistical extrapolations is0
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Fig. 1. Dose response data adapted fcalculated and selected as the POD. Not all statistical extrapolations
are used. Only those that meet statistical test criteria for goodness
of ﬁt. The average of eight models meeting minimum requirements
for goodness of ﬁt was used to derive the POD (30,404 ppm min).
The modelled dose-response results (for eight mathematical
models) are provided in Fig. 3 and are tabulated in Table 4. The
lower conﬁdence limit of the benchmark concentration is referred
to as the BMCL.4.5. Selection of uncertainty factors
The uncertainty factors considered and selected are presented in
Table 4. The total uncertainty factor evaluates the available data
from four aspects: human variability (kinetic and dynamic), ade-
quacy of the database, and the use of a non-chronic study for se-
lection of the POD. Interspecies extrapolationwas not considered as
human data were employed to derive the POD.
Occupational assessments based on human data typically apply
a factor of 1e3 depending on the robustness of the data (Maier
et al., 2010). For MOF renal toxicity has been observed in several
different studies involving several different species (including
humans) and the mode of action is well understood. The NOAEL for
clinical renal toxicity has been deﬁned with reasonable conﬁdence.
Repeat exposure animal toxicity studies are available for critical
endpoints for occupational exposure standard development.
Developmental toxicity was investigated following exposure to
trace (2 ppm) and sub-anaesthetic (60 ppm) concentrations for 4 h
a day on gestation days 6 through to 15. The NOEL for this studywas
60 ppm (i.e. higher than the POD). At higher concentrations in
repeat exposure studies with rats (Wistar and Fischer 344), guinea
pigs or rabbits resulted in evidence of liver toxicity. These results
are discussed in Table 9 and Section 5.2.
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Fig. 2. Dose-response data grouping. 1 The maximum dose (192,000 ppm min MOF) selected for benchmarking as there were no incidences recorded for Dose group 1. 2
Conservatively the lowest dose concentration (240,000 ppm min MOF) used for benchmarking for Dose group 2. 3 Conservatively the lowest dose concentration (432,000 ppm min
MOF) used for benchmarking for Dose Group 3. 4 One dose in this grouping, 672,000 ppm min MOF used for benchmarking for Dose group 4. 5 One dose in this grouping,
864,000 ppm min MOF used for benchmarking for Dose group 5.
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related factors for general healthy adults (Pohl and Scinicariello,
2011). Dorne et al. (2005) include factors for CYP2E1 enzymes of
1.5 and 1.8 for the 95th and 99th percentile of the population,
respectively (as compared to the median value).
Given that the assessment is for workers (a relatively healthy
subpopulation of adults) and the critical effect is well characterised
in human studies, the total uncertainty factor of 3 was selected.4.6. Derivation of the maximum exposure level (MEL)
The derivation of the MEL follows conventional risk assessment
methodology using the benchmark dose modelling approach. As
previously described, benchmark dose software was used to model
the dose-response relationship between MOF and the critical effect
(based on the ﬁndings of the key study). The POD was derived from
the average of the modelled BMCL (30,404 ppm min).
The derivation is intended as an eight hour time weighted
exposure thus adjustment for averaging time was made. The 8-hr
POD expressed as an 8 h average is 63 ppm.
An uncertainty factor of 3 was applied to the 8-hr POD to derive
the MEL due to human toxicodynamic variability. Table 4 summa-
rises the steps and decisions made to derive the occupational
maximum exposure level. This includes the goodness of ﬁt (GOF)
evaluation for each of the BMC models utilised. All models exceed
the US EPA (2012) recommended cutoff p-value of 0.1 and have a
small Akaike’s Information Criterion (AIC) value. Taken together
with the visual inspection of curve ﬁt, the average BMC10 and
BMCL10 was used as the POD. The resulting 8 h MEL is 15 ppm.
The no observed adverse effect level in the key study wasbetween 96,000 ppmmin and 264,000 ppmmin or expressed as an
8 h concentration, 200 ppm and 550 ppm. Thus the BMD is between
3.2 and 8.5 times lower than the NOAEL observed in the study. The
derivation of an MEL using the NOAEL approach would result in an
MEL of between 66 and 183 ppm assuming the same uncertainty
factor of 3. The factor between the NOAEL and the BMD provides
additional conﬁdence that the uncertainty factor selected is
appropriate.
The BMD approach is generally considered reliable and prefer-
able where data sets include two or more dose groups given that
the entire dose response curve is utilised and the assessment is not
reliant on any biases in dose selection.5. Discussion
5.1. Consideration of exposure
5.1.1. Monitoring data
Methoxyﬂurane may be administered within an ambulance’s
patient compartment. The relatively small size of the compartment
and the volatile nature of methoxyﬂurane indicate that occupa-
tional exposure to ambulance ofﬁcers can occur. Ambulance ofﬁ-
cers have reported odour (often described as characteristic or
fruity) during its administration. The frequency of occupational
exposure will vary depending on the frequency of indicated uses
during a day, the duration of patient inhalation, ventilation at the
site of use and other administrative controls (trip duration and
number in a working period). Given these variables, the magnitude
of exposure is best considered through occupational exposure
monitoring.
Fig. 3. Benchmark dose modelling results (using US EPA BMDS Wizard).
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Table 4
Summary of derivation of maximum exposure level (MEL).
Modela Goodness of ﬁt BMC10 (ppm min) BMCL10 (ppm min) Ratio BMC/BMCL
p-value AIC
Gamma 0.324 22.908 1.2Eþ05 25074 4.79
Dichotomous-Hill LogLogistic 0.324 22.802 1.4Eþ05 20455 6.84
Logistic 0.301 23.229 99591 52483 1.90
Probit 0.305 23.193 94306 51653 1.83
LogProbit 0.332 22.759 1.4Eþ05 21779 6.43
Weibull 0.323 23.009 98004 24772 3.96
Quantal-Linear 0.430 22.020 37760 22320 1.69
Multistage 3a
Multistage 2
0.312 23.035 1.0Eþ05 24699 4.05
POD (average of all modelled BMCL10) expressed as ppm min 103,708 30,404 e
POD expressed as 8 h average 216 63
Selection of POD 63
Uncertainty factor selection
Interspecies NA NA
Human variability e toxicokinetics 1
Human variability e toxicodynamics 3
Adequacy of database 1
Less than working life 1
MEL ppm 15
Shaded cell is the selected POD used for derivation of the MEL.
a For the Multistage 3 model, the beta coefﬁcient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 2 model.
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and Gately (1999) and Coffey (2011)).
Hibbs and Gately (1999) measured MOF exposure of Ambulance
Ofﬁcers (AO’s) in New South Wales (NSW) Australia during typical
exposure conditions. During a two month period 302 samples (152
from Treating Ofﬁcers and 150 samples from Drivers) were
collected and assayed for MOF. Exposure estimationwas performed
by the collection of breathing zone air samples using passive do-
simeters. The sampling rate allowed for measurement of exposures
as low as 0.2 ppm for less than 1 h. The ambulance stations chosen
were selected based on their previous high MOF usage.
The 8 h TWA exposure was calculated by Hibbs and Gately
(1999) and presented in Table 5. The exposures are well below
the derived MEL of 15 ppm (8 h TWA).
Duration of exposure and magnitude of exposure were not
related indicating that the exposures to MOF were acute and
intermittent. The vast majority of AO’s were exposed only once per
day and the mean exposure period was 21 min.
Coffey (2011) measured MOF exposure of AO’s from the St John
Ambulance Service in Western Australia during typical exposure
conditions. During a one month period a total of 45 samples were
collected on Ambulance Attendants, 45 on Ambulance Drivers and
44 in treatment areas. Exposure estimation was performed by the
collection of breathing zone (attendants and drivers) air samples
using passive dosimeters (3 M organic vapour monitoring (OVM)
badges). The samples were collected during the event deﬁned as
the duration of exposure during treatment. The duration of expo-
sure ranged between 15 min and 53 min (mean 30 min). The
average 8-h TWA for attendants and drivers are 0.23 and 0.15 ppm
respectively. The breathing zone concentrations ranged between
0.2 ppm and 7 ppm per treatment. The maximum 8-h TWA wasTable 5
Average MOF exposure of ambulance ofﬁcers (Hibbs and Gately, 1999).
Exposure Driver Training ofﬁcer
8 h average
Geometric mean (ppm) 0.03 0.06
*Prepared from Hibbs and Gately (1999) and subsequent personal correspondence
(SHE Paciﬁc, 2000).estimated at 1.5 ppm. The vast majority of AO’s were exposed only
once per day and the mean exposure period was 30 min. Expressed
either as an exposure per treatment or as an 8 h time weighted
average the breathing zone concentrations are all well below the
derived MEL of 15 ppm (TWA).
One of the uncertainties in the derivation of the MEL is the
potential accumulation of serum ﬂuoride on repeat exposure to
MOF over a working week. The relationship between serum ﬂuo-
ride and MOF inhalation exposure from Cousins and Mazze (1973)
is presented in Fig. 4. The line of best ﬁt was explored for this
dataset and is presented in Fig. 3. Using the equation derived from
the line of best ﬁt, the serum ﬂuoride concentrations at the MEL
and 99 breathing zone exposures reported by Coffey (2011) are
plotted into Fig. 4. The estimated serum ﬂuoride concentrations at
the MEL and at the maximum ambulance ofﬁcer exposure are 112
and 285 times lower than the threshold for kidney toxicity of
40 mM. The maximum ambulance ofﬁcer exposures are likely to
reﬂect the peak serum ﬂuoride concentrations of occupationally
exposed individuals. The estimates provide additional conﬁdence
in the approach taken to derive the MEL.
Both the results of Corbett & Ball. (1971) and Strum et al. (1991)
show that sub-anaesthetic concentrations of MOF are rapidly
eliminated following inhalation with most of the elimination
occurring within several hours. Using the mean exposure time re-
ported in Coffey (2011) and the Ratio of Time for Elimination/
Duration of Exposure presented in Table 1 from an analysis of
Corbett & Ball. (1971), the time to elimination is anticipated to be
within one working day even if repeat intermittent exposure
occurred. The patients exposed to MOF in Cousins and Mazze
(1973) were exposed over an average of 4 h, a relevant timeframe
for the present assessment.5.1.2. Workplace exposure modelling
Workplace exposure (vapour) modelling is a tool routinely used
for predicting indoor air concentrations for volatile chemicals. A
two-phase steady-state-logarithmic decay model of MOF vapour
concentrations in usage rooms was developed; ‘Usage Room’ is
intended to cover use in an ambulance, clinic, aircraft or other
enclosed space. The model used an initial steady-state then loga-
rithmic decay conditions according to standard volatilization
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vapour concentration in an enclosed space is dictated by the rate of
evaporation of the compound, the volume of the room, and the
ventilation rate. The steady state phase persists until the compound
has fully evaporated, at which point vapour concentration is
calculated according to exponential decay controlled by the venti-
lation rate (second phase). The model was based on the following
underlying assumptions and calculations:
1. Usage over eight hour shift is assumed at one vial per hour (8
vials) and the worst case is assumed at one vial per half hour (16
vials). Vials are used at regular intervals, i.e. a new vial is
dispensed into the inhaler chamber every hour, or every half-
hour. This is a highly conservative assumption as it assumes
intensive usage. Typical usage would be less than this.
2. The entire contents of the vial (4230 mg MOF) evaporate at a
steady state until the inhaler is dry.
3. Dispersal throughout the usage room is immediate with com-
plete mixing, i.e. concentration gradients do not occur.
4. The compound does not react with the atmosphere and is not
absorbed by the patient; all methoxyﬂurane inhaled is exhaled
into the atmosphere (i.e. reaction rate, k, of zero). In reality, the
patient absorbs in the range 65e81% of MOF (Holaday et al.,
1970; Yoshimura et al., 1976; Sakai and Takaori, 1978).
5. Empirical data (measurements of MOF leaving the chamber over
time) suggest that the minimum evaporation time is 20 min,
with an effective usage time of 30 min to 1 h, depending on
usage type (continuous or intermittent breathing). Evaporation
rate, E, is calculated as:
Eðmg=hÞ ¼ mass in vial
effective usage time
Because the minimum usage time gives the highest eight-hour
averaged concentration, 0.3333 h (20 min) was assumed:
Eðmg=hÞ ¼ 4230mg
0:3333 h
Eðmg=hÞ ¼ 12691mg=h6. The steady state concentration (Css; mg/m3) is maintained over
the effective usage time, after which the inhaler chamber is dry,
and is:
Css ¼
E
V
nþ k
Where V is the volume of the room, n is the number of air changes
per hour, and k is the reaction rate (assumed to be zero as previ-
ously described).
7. Css; mg/m3 was converted to ppm, assuming 25 C, standard
pressure, and molecular weight of MOF of 167.94 g/mol:
CssðppmÞ ¼ C0x 24:45molecular weight8. Once the inhaler is dry, the concentration of vapour decreases
only due to air changes within the room (i.e. does not react with
atmosphere and is not absorbed by the patient; reaction rate of
zero) according to the relationship:
Ct ¼ C0ent
where Ct is the concentration in ppm at time t in hours after release,
C0 is the initial concentration after full evaporation of the vial’s
contents (i.e. Css) and n is the number of air changes per hour.
9. The average concentration over an eight-hour shift (8 h TWA) is
the weighted average of concentrations calculated for ﬁve
minute time steps
Cave ¼ 5SðC0 þ C0:083 þ…C8Þ48010. The peak 1 h TWA is the average vapour concentration over
the ﬁrst hour after opening the vial.
Cave ¼ 5SðC0 þ C0:083 þ…C1Þ60
Table 6
Input parameters for vapour modelling.
Parameter Scenario TR (treatment room) Ambulance
ACH (1/h) Base 6 46
Min. ventilation 3 26
Max. ventilation 15 100
Volume (m3) Base 32.4 11.25
Initial vapour conc. (ppm) Base 10 4
Min. ventilation 19 6
Max. ventilation 4 1.64
Effective usage time (h) Base 0.3333 0.3333
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time step is the sum of the vapour remaining after decay of
the most recent vial plus the vapour remaining from previ-
ous vials up to 2 h in the past (>2 h the vapour contribution is
negligible).
The corollary of these assumptions is that the calculated MOF
vapour concentration is an average for the usage room volume
overall, not a speciﬁc exposure level for a room attendant. Staff in
close proximity to a patient using a MOF inhaler may be exposed to
a greater concentration than that calculated at least for a short
period. However, the model is conservative in its approach in that
absorption of MOF by the patient has been discounted to zero, and
it assumes the continuous presence of the attendant in the room
during the 8 h shift.
The input parameters/variables used in the model were the
volume of the usage room, number of air changes per hour (ACH)
and number of vials used per day. There is a moderate degree of
uncertainty in the ACH assumptions because there are a range of
ventilation systems in use, e.g. ducted building ventilation in
treatment rooms and fan-driven air conditioning or ventilation in
ambulances and aircraft. The ACHs have been interpolated from
treatment room design guidelines and observations in US ambu-
lances rather than being taken from direct measurements under
Australian conditions. Base, minimum and maximum values used
are given in Table 6 Usage roomswere assumed to be an emergency
department/hospital, consulting treatment room (TR) and the pa-
tient compartment of an ambulance or aircraft. The standard
dimension and ventilation of the TR was taken from Australian
Health Infrastructure Alliance (AHIA) Australasian Health Facility
Guidelines (AusHFG) appendices A and D, and were 12 m2  2.7 m
(32.4 m3) and 6 ACH, respectively. These values were used as a
base-case in the model. Lower and upper ACH values were takenTable 7
Output vapour concentrations (ppm) from model.
Basea
1 vial/h 2 vial/h
TR 8 h TWA 0.74 1.48
Ambulance 8 h TWA 0.21 0.43
a 6 ACH for TR, 46 ACH for ambulance.
b 3 ACH for TR, 26 ACH for ambulance.
c 15 ACH for TR, 100 ACH for ambulance.
Table 8
Comparison of modelled and observed MOF vapour concentrations (ppm) in an ambulan
(All ppm) Modelled in patient compartment (1 vial/h) wi
8 h TWA e mean 0.21 (base)
8 h TWA e median e
8 h TWA e range 0.1 (min) e 0.39 (max)from US ASHRAE standard 62e2001 Ventilation for Acceptable In-
door Air Quality Addendum and HICPAC (2003).
Typically (Munro and Hayes, 2009) an ambulance has a patient
compartment volume of 11.25 m3. Ventilation rates observed in US
ambulances are 26e46 ACH (Seitz et al., 1996), and therefore, the
base-case for the ambulance was 11.25 m3 and 46 ACH, with 26 and
100 ACH taken as lower and upper extremes, representing an
approximate two-fold increase and decrease over the baseline
condition. This ACH range is supported by measurements in pas-
senger vehicles with the windows closed, the ACH rates of which
vary from <2 to >40 depending on the vehicle’s velocity and
whether the air conditioning and vents were on or off (Ott et al.,
2008).
The modelling was intended to reﬂect ACH variability in
ambulance and treatment rooms. The ACH values used for ambu-
lances are also applicable to other modes of transport with com-
parable ACH such as aircraft.
The ﬁnal variable tested was effective usage time. Vapour con-
centration is inversely proportional to the usage time, so minimum
(20 min or 0.3333 h) and maximum (1 h) usage times were
compared for their effect on 8 h and 1 h TWA in the TR. The shorter
exposure at a higher concentration gave higher TWA, so this usage
pattern was adopted throughout.
The Penthrox inhaler is ﬁtted with an activated carbon (AC)
chamber, which adsorbs MOF exhaled by the patient. Data supplied
by the manufacturer (Munro and Hayes, 2009) indicates >86%
reduction in fugitive MOF when this is installed. This was included
in the model as an AC reduction factor applied to the model
outputs.
The model was calibrated against MOF vapour concentrations
observed in ambulances (Coffey, 2011). Only ACH and not room
volume was varied during calibration of the modelling because
initial vapour concentration depends on ACH, ACH values wereMin. vent.b Max. vent.c
1 vial/h 2 vial/h 1 vial/h 2 vial/h
1.93 3.86 0.24 0.49
0.39 0.77 0.1 0.2
ce patient compartment.
th AC chamber Observed near attendant without AC chamber
0.233
0.150
0.048e0.463 (with single outlier 0.048e1.458)
J. Frangos et al. / Regulatory Toxicology and Pharmacology 80 (2016) 210e225222uncertain while room volumes can be deﬁnitively determined, and
sensitivity analysis demonstrated that room volume and ACH had
similar effects on 8 h TWA. Number of vials was either 1 or 2, at a
usage rate of 1 per hour or per half-hour as appropriate, and the
scenarios were tested at both usage rates. Outputs of the model
under the four scenarios (1 or 2 vials/h, minimum, maximum or
base ventilation) are given in Table 6. The AC reduction factor of 85%
has been applied to both Ambulance and TR settings as the AC
Chamber is typically used in both clinical settings. Ambulance
outputs without the AC reduction factor are compared to obser-
vations made by Coffey (2011). Outputs are expressed as a function
of ventilation (ACH), and are therefore subject to the uncertainty
inherent in the ACH rates selected. Reliable estimates of concen-
trations for speciﬁc usage situations will rely on acquisition of
ventilation measurements for those situations.
The model estimates are considered reasonable and reliable for
estimation purposes. Using the assumed ACH values, modelled
outputs (AC chamber is in use) from the base-case ambulance
scenario are similar in magnitude to the measured concentrations
(where the AC chamber is not in use) in the vicinity of the attendant
in ambulance patient compartment (0.21 ppm modelled vs.
0.233 ppmmean and 0.150 ppmmedian observed) (Tables 7 and 8).0.00
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Fig. 5. Modelled vapour concentrations in ambulance patient compartment at inten-
sive usage rate of 1 vial/h (top) or 2 vial/h (bottom) with AC Chamber. A volume of
11.25 m3 and ACH of 46/h was assumed. Each peak represents a new vial being
dispensed. The TWA (0.21, 0.43 ppm) and peak concentrations remain below the MEL
and the concentration of MOF returns to low levels between treatments.The model demonstrates the importance of ACH on occupa-
tional exposure and 8 h TWA. It shows that multiple uses of MOF
during a working day has an incremental effect on 8 h TWA. Mul-
tiple uses have a smaller effect on 8 h TWA in the ambulance (ACH
range modelled 26e100/h) compared to the TR (ACH range 3e15/
h). This is because vapour concentrations are dependent on ACH in
a logarithmic decay relationship, and decreases rapidly once the
MOF in the Inhaler is exhausted (see Figs. 5 and 6 for 1 vial/hour
and 2 vial/hour decay curves of ambulance and TR, respectively). It
is important that none of the scenarios modelled predicted an 8 h
TWA in excess of 15 ppm -maximum predicted 8 h TWA is 3.9 ppm
under poor ventilation conditions and 2 vials/h in TR, and 0.8 ppm
under the same conditions in the ambulance patient compartment.
It should also be noted that this model does not account for MOF
absorbed by the patient upon inhalation from the inhaler, which
will tend to lead to a further over-estimation of occupational
exposure. Approximately 19%e35% of methoxyﬂurane is exhaled
unchanged (Holaday et al., 1970; Yoshimura et al., 1976; Sakai and
Takaori, 1978).
Although the focus of the modelling is on 8 h average concen-
tration the modelling also investigated minimum ventilation re-
quirements to keep the peak concentration less than 15 ppm.0.00
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Fig. 6. Modelled MOF vapour concentrations in the TR, at intensive usage rates of
1(top) or 2 (bottom) vials/h with AC Chamber, assuming 32.4 m3 volume and 6 ACH.
Each peak represents a new vial being dispensed. The TWA (0.74, 1.5 ppm) and peak
concentrations remain below the MEL (15 ppm) and the concentration of MOF returns
to low levels between treatments.
Table 9
Summary of dose response for liver toxicity compared to proposed maximum exposure level.
Study description Exposure in ppm min Effects Margina
Chenoweth et al., 1972
Rats, guinea pigs and rabbits exposed to 200 ppm MOF for
7 h/d, 5 d/wk for 7 wks
84,000 per day for 7 weeks Changes in liver function parameters (SGOT,
SPGT), focal hepatic inﬁltration and changes in
relative liver weights.
3
Plummer et al. (1985)
Rats exposed to 50 ppm 24 h/d, continuously for 14 weeks
72,000 continuously (24 h/d) for 14
weeks (i.e. this could be interpreted as
6,480,000 ppm min)
Changes in liver weights. Hepatocellular
degeneration and necrosis and fatty inﬁltration.
2
Egar et al. (1978)
Mice exposed to up to 3000 ppm for 2 h/d for last half of
pregnancy and 24 exposures at 2e3 day intervals after
delivery
360,000 per day (total of 28 exposures) No changes in liver weights, no microscopic
liver damage observed.
12
Point of Department (POD) ¼ 30,404 ppm min (based on threshold for nephrotoxicity, refer to Table 4) 1
a Margin between Liver effect level and point of departure (POD) (i.e. liver effect concentration (ppm min) ÷ POD (ppm min).
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following conditions:
1 vial per hour at an ACH of 3; and
2 vial per hour at an ACH of 3.5.
The peak is always less than 15 ppm in a treatment room under
the following conditions:
1 vial per hour at an ACH of 1.15; and
2 vial per hour at an ACH of 1.95.
Assuming high intensity use of methoxyﬂurane the minimum
ventilation requirements to keep both the TWA and peak concen-
trations low are below typical as well as recommended ventilation
rates for ambulances (and other vehicles such as aircraft) and
treatment rooms demonstrating that the MEL is achieved in worst
case simulations of occupational exposure.
The MEL derived is at least 50 times higher than the mean
measured observed exposure level for ambulance workers and
medical staff involved in supervising the use of Penthrox (refer to
Table 8).
Using a model that conservatively estimates occupational
exposure assuming high intensity use and typical (base case)
ventilation circumstances, the MEL derived is at least 10 times
higher than the estimated TWAs.
5.1.3. Odour threshold
The odour detection threshold for MOF was determined using
dynamic olfactometry (Munro and Hayes, 2015). This technique
involves repeated presentation both of a diluted odour sample and
an odour-free air stream to a panel of qualiﬁed assessors through
two adjacent ports on the olfactometer. Ten trials with six people
were conducted in accordance with the methodology described by
the Australian Standard AS/NZS 4323.3; 2001.
The odour detection threshold is reported to range between 0.13
and 0.19 ppm (geometric mean 0.15 ppm). Odour could therefore be
detected during exposure but the detection threshold was well
below the MEL.
5.2. Consideration of repeat dose liver toxicity
Severe liver toxicity followingMOF exposure during anaesthesia
and analgesia has been observed on rare occasions and is consid-
ered to be an idiopathic reaction. This form of liver toxicity is
postulated to be mediated by the immune system probably
involving direct toxicity due to reactive metabolites (Kenna and
Jones, 1995). This phenomenon is relatively well understood as it
bears similarities to halothane hepatitis, a well described thoughrare consequence of high and repeat dose exposure.
An underlying presupposition in deriving the MEL is that the
critical effect is nephrotoxicity. The biotransformation of MOF re-
sults in the release of inorganic ﬂuoride, which inhibits chloride
transport in the ascending limb of the loop of Henle (Sweeney and
Bromilow, 2006). The release of ﬂuoride is directly related to the
duration of exposure, the concentration of MOF and the rate of
biotransformation (Sweeney and Bromilow, 2006). Chenoweth
et al. (1972) reported non-speciﬁc and adaptive changes to the
liver in response to prolonged, high level exposure of several spe-
cies to MOF, quite unlike the clinical and pathological features of
halothane hepatitis and as described in the very few cases of
hepatotoxicity associated withMOF. Although there are few studies
investigating liver toxicity and MOF, the available studies together
with the longstanding history of clinical use indicate that protec-
tion from kidney effects is very likely also to protect against
hepatotoxicity.
Table 9 compares these effect levels to the point of departure
chosen for MEL derivation (30,404 ppm min) with the effect levels
for liver from repeat dose animal experiments. The POD is between
2 and 12 times lower than the effect levels for liver toxicity sup-
porting the selection of kidney as the POD.6. Conclusions
The analysis in this paper highlights the value of a combination
of the breadth and depth of a dataset obtained for clinical evalua-
tion with modern risk assessment techniques used to derive
occupational exposure levels. The toxicity database of methoxy-
ﬂurane is relatively unique given its history of use in anaesthesia
(high acute dose) and exposure to lower intermittent dosage as an
analgesic. Translating this dataset to an intermittent occupational
exposure (low dose) is demonstrated within the paper. The inter-
pretation and extrapolation of clinical toxicity data for occupational
risk assessment is detailed taking account of the change in pattern
of the exposure from a high concentration single exposure to a low
concentration intermittent occupational exposure. A maximum
exposure limit (MEL) of 15 ppm as a time weighted average has
been derived with a degree of conservatism to match the un-
certainties inherent in the toxicity dataset. The MEL of 15 ppm is a
conservative benchmark that should allow a considerablemargin of
protection of occupational health during the responsible use of
Penthrox.
Similarly conservative assumptions have been employed in a
modelling exercise to explore possible ambient exposures of staff
supervising the self-administration of MOF in a variety of settings
related to likely working practices in ambulances, treatment rooms
and aircraft. The predicted exposures were checked against real-
world measurements and both indicated a signiﬁcant margin of
J. Frangos et al. / Regulatory Toxicology and Pharmacology 80 (2016) 210e225224safety of between 10 and 50 even when very conservative as-
sumptions were made about the possible use of MOF.
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